- Email: [email protected]
Subject Index to Volume 5
Brachytherapy 5 (2006) 268–271
Subject Index to Volume 5
A Abstracts American Brachytherapy Society annual meeting presentations, 70 Acute myocardial infarction (AMI) prostate brachytherapy seed migration to RCA in association with (case report), 262 Adenocarcinoma localized, quality assurance in RTOG permanent prostate implant protocol for, 152 prostate, dosimetry of permanent implant versus high-dose-rate brachytherapy for, 251 American Brachytherapy Society annual meeting presentations, 70
B Bladder comparison of ICBT doses based on orthogonal films and CECT in cervical cancer, 223 Book review Crook: Basic and Advanced Techniques in Prostate Brachytherapy, Vol. 4, p. 304; erratum, 61 Brachytherapy dosimetric comparison of 3DCRT and IMRT and Mammosite for partial breast irradiation, 183 high-dose-rate endobronchial, versus with EBRT, for symptom palliation in patients with non–small-cell lung cancer, 189 intracavitary and interstitial, high-dose-rate, quality assurance of treatment plans for, 56 low-dose-rate versus high-dose-rate, for cervical cancer, outcomes of, 49 seed, for prostate cancer, technique to determine accurate urethral dosimetry after, 27 single-dose, for dysphagia palliation in esophageal cancer, predictors of outcomes of, 41 ultrasound-guided, for prostate cancer, real-time CT-based postplanning dosimetry during, 147 Breast brachytherapy single source, versus EBTF, for left breast cancer, lung and cardiac tissue doses in patients, 235 Breast cancer. see also Breast brachytherapy dosimetric comparison of 3DCRT and IMRT and Mammosite, 183 early-stage, evaluation of surface radiation dose and dose gradient using Mammosite applicator, 230 left, lung and cardiac tissue doses in SSB versus EBTF for, 235
C Cancer recurrence gynecologic, PHDRB for, 203
1538-4721/06/$ – see front matter doi:10.1016/S1538-4721(06)00273-X
Catheterization relation to urinary morbidity and International Prostate Symptom score after 125I prostate brachytherapy, 9 Cervical cancer comparison of ICBT doses to tumor, rectum and bladder based on orthogonal films and CECT in, 223 outcomes of low-dose-rate ICBT versus high-dose-rate ICBT for, 49 and vaginal cancer, outcomes of high-dose-rate brachytherapy with EBRT for, 218 Computed tomography (CT) contrast enhanced, versus orthogonal films, comparison of ICBT doses to tumor, bladder and rectum, 223 real-time, for postplanning dosimetry during ultrasound-guided brachytherapy for prostate cancer, 147 Contrast enhanced computed tomography (CECT) versus orthogonal films, in comparison of ICBT doses to tumor, bladder and rectum, 223 Coronary artery right, prostate brachytherapy seed migration to, in association with AMI (case report), 262 Customized stranded seed (CSS) versus USS, in TIPPB, dosimetry of, 244
D Dose escalation of high-dose-rate brachytherapy boost for prostate cancer, outcomes of, 256 Dose homogeneity in early stage breast cancer using Mammosite applicator, evaluation of, 230 Dosimetry in 3DCRT versus IMRT and Mammosite for partial breast irradiation, 183 in high-dose-rate brachytherapy versus permanent implant for prostate adenocarcinoma, 251 in ICBT, to tumor, rectum and bladder based on orthogonal films and CECT, 223 postimplant descriptive analysis from RTOG 0019, 239 and embolization rates, of suture-embedded versus loose seed implants for prostate brachytherapy, 165 transrectal ultrasonography, effect of interobserver variability on, 174 real-time CT-based postplanning, during ultrasound-guided brachytherapy for prostate cancer, 147 urethral, after seed brachytherapy for prostate cancer, technique to determine accuracy of, 27 of USS versus CSS, in TIPPB, 244 Dysphagia palliation in esophageal cancer, predictors of outcomes of single-dose brachytherapy for, 41
Subject Index / Brachytherapy 5 (2006) 268–271 E
I
Embolization rates and postimplant dosimetry, of suture-embedded versus loose seed implants for prostate brachytherapy, 165 Esophageal cancer predictors of outcomes of single-dose brachytherapy for dysphagia palliation in, 41 External beam radiation therapy (EBRT) versus with HDREB, for symptom palliation in patients with non–small-cell lung cancer, 189 with high-dose-rate brachytherapy, for gynecologic cancer, outcomes of, 218 with three-dimensional computer-optimized high-dose-rate brachytherapy, for localized prostate cancer, outcomes of, 157 External beam tangent field (EBTF) versus SSB, for left breast cancer, lung and cardiac tissue doses in, 235
125I
F First fraction optimization (FFO) versus IFO, for multichannel vaginal cuff high-dose-rate brachytherapy, 211; (editorial), 216
G Geometric optimization IFO versus FFO, for multichannel vaginal cuff high-dose-rate brachytherapy, 211; (editorial), 216 Gynecologic cancer cervical and vaginal cancer, outcomes of high-dose-rate brachytherapy with EBRT for, 218 locally advanced and recurrent, PHDRB for, 203
269
prostate brachytherapy relation of International Prostate Symptom score to urinary morbidity and catheterization after, 9 transperineal interstitial permanent, seed migration to the vertebral venous plexus (case report), 127 Image guidance phantom experiments of robot-assisted transrectal ultrasound in prostate brachytherapy, 14 Individual fraction optimization (IFO) versus FFO, for multichannel vaginal cuff high-dose-rate brachytherapy, 211; (editorial), 216 Intensity-modulated radiation therapy (IMRT) versus 3DCRT and Mammosite, for partial breast irradiation, dosimetric comparison of, 183 International Prostate Symptom score relation to urinary morbidity and catheterization after 125I prostate brachytherapy, 9 Interobserver variability effect on transrectal ultrasonography-based postimplant dosimetry, 174 Interstitial brachytherapy and ICBT, high-dose-rate, quality assurance of treatment plans for, 56 transperineal permanent prostate dosimetric analysis of USS versus CSS in, 244 125I, seed migration to the vertebral venous plexus (case report), 127 Intracavitary brachytherapy (ICBT) doses to tumor, rectum and bladder based on orthogonal films and CECT, 223 high-dose-rate versus low-dose-rate, for cervical cancer, outcomes of, 49 and interstitial brachytherapy, high-dose-rate, quality assurance of treatment plans for, 56
L H Head and neck cancer PHDRB and salvage surgery in previously irradiated patients with, 32 Heart tissue doses, in SSB versus EBTF for left breast cancer, 235 High-dose-rate brachytherapy boost, outcomes of dose escalation trial for prostate cancer, 256 with EBRT, for gynecologic cancer, outcomes of, 218 intracavitary and interstitial, quality assurance of treatment plans for, 56 versus low-dose-rate ICBT, for cervical cancer, outcomes of, 49 versus low-dose-rate brachytherapy, in prostate cancer treatment, 1 counterpoint, 5 rebuttal, 8 rebuttal, 7 Mammosite, evaluation of surface radiation dose and dose gradient in early stage breast cancer using, 230 multichannel vaginal cuff, IFO versus FFO for, 211; (editorial), 216 perioperative for locally advanced and recurrent gynecologic cancer, 203 and salvage surgery, in previously irradiated head and neck cancer patients, 32 versus permanent implant, for prostate adenocarcinoma, dosimetry of, 251 three-dimensional computer-optimized, with EBRT, for localized prostate cancer, outcomes of, 157 twice-daily, for medically inoperable uterine cancer, 118 High-dose-rate endobronchial brachytherapy (HDREB) versus with EBRT, for symptom palliation in patients with non–small-cell lung cancer, 189 Hypofractionation in high-dose-rate brachytherapy boost for prostate cancer, outcomes of, 256
Low-dose-rate brachytherapy versus high-dose-rate brachytherapy, in prostate cancer treatment, 1 counterpoint, 5 rebuttal, 8 rebuttal, 7 intracavitary, versus high-dose-rate brachytherapy, for cervical cancer, outcomes of, 49 for prostate cancer, preplanning versus intraoperative planning, 139 counterpoint, 143 rebuttal, 146 rebuttal, 145 Lung cancer non–small-cell, HDREB versus with EBRT for symptom palliation in patients with, 189 Lung tissue doses, in SSB versus EBTF for left breast cancer, 235
M Mammosite versus 3DCRT and IMRT, for partial breast irradiation, dosimetric comparison of, 183 evaluation of surface radiation dose and dose gradient in early stage breast cancer using, 230 Medical malpractice in radiation oncology (case report), 131 commentary (editorial), 135 Multichannel vaginal cuff high-dose-rate brachytherapy, IFO versus FFO for, 211; (editorial), 216 Myocardial infarction acute, prostate brachytherapy seed migration to RCA in association with (case report), 262
270
Subject Index / Brachytherapy 5 (2006) 268–271
N Non–small-cell lung cancer HDREB versus with EBRT for symptom palliation in patients with, 189
O Orthogonal radiographs versus CECT, in comparison of ICBT doses to tumor, bladder and rectum, 223 Outcomes dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer, 256 high-dose-rate brachytherapy with EBRT for gynecologic cancer, 218 low-dose-rate ICBT versus high-dose-rate ICBT for cervical cancer, 49 single-dose brachytherapy for dysphagia palliation in esophageal cancer, predictors of, 41 three-dimensional computer-optimized high-dose-rate brachytherapy with EBRT for localized prostate cancer, 157
rebuttal, 8 rebuttal, 7 localized, outcomes of three-dimensional computer-optimized highdose-rate brachytherapy with EBRT for, 157 outcomes of dose escalation trial of high-dose-rate brachytherapy boost for, 256 preplanning versus intraoperative planning of low-dose-rate brachytherapy for, 139 counterpoint, 143 rebuttal, 146 rebuttal, 145 real-time CT-based postplanning dosimetry during ultrasound-guided brachytherapy for, 147 technique to determine accurate urethral dosimetry in seed brachytherapy for, 27 Prostate-specific antigen (PSA) bounce of, mimics biochemical relapse after permanent prostate brachytherapy, 122
Q P Palliative treatment single-dose brachytherapy, for dysphagia in esophageal cancer, predictors of outcomes of, 41 of symptoms in patients with non–small-cell lung cancer, HDREB versus with ERB for, 189 Partial breast irradiation dosimetric comparison of 3DCRT and IMRT and Mammosite for, 183 Perioperative high-dose-rate brachytherapy (PHDRB) for locally advanced and recurrent gynecologic cancer, 203 and salvage surgery, in previously irradiated head and neck cancer patients, 32 Permanent implant versus high-dose-rate brachytherapy, for prostate adenocarcinoma, dosimetry of, 251 prostate dosimetric analysis of USS versus CSS in, 244 125I, seed migration to the vertebral venous plexus (case report), 127 for localized adenocarcinoma, quality assurance in RTOG protocol of, 152 Phantom experiments of robot-assisted transrectal ultrasound in prostate brachytherapy, 14 Prostate adenocarcinoma dosimetry of permanent implant versus high-dose-rate brachytherapy for, 251 Prostate brachytherapy descriptive analysis of postimplant dosimetry from RTOG 0019, 239 effect of interobserver variability on transrectal ultrasonography-based postimplant dosimetry, 174 125I relation of International Prostate Symptom score to urinary morbidity and catheterization after, 9 transperineal interstitial permanent, seed migration to the vertebral venous plexus (case report), 127 permanent for localized adenocarcinoma, quality assurance in RTOG protocol of, 152 PSA bounce mimics biochemical relapse after, 122 transperineal interstitial, dosimetric analysis of USS versus CSS in, 244 with robot-assisted transrectal ultrasound guidance, phantom experiments, 14 seed migration to RCA in association with AMI (case report), 262 using suture-embedded and loose seed implants, postimplant dosimetry and embolization rates of, 165 Prostate cancer. See also Prostate brachytherapy high-dose-rate versus low-dose-rate brachytherapy for, 1 counterpoint, 5
Quality assurance in RTOG permanent prostate implant protocol for localized adenocarcinoma, 152 of treatment plans for interstitial and intracavitary high-dose-rate brachytherapy, 56
R Radiation dose surface, in early stage breast cancer using Mammosite applicator, evaluation of, 230 Radiation oncology medical malpractice crisis in (case report), 131 commentary (editorial), 135 Radiation therapy external beam with high-dose-rate brachytherapy, for gynecologic cancer, outcomes of, 218 with three-dimensional computer-optimized high-dose-rate brachytherapy, for localized prostate cancer, outcomes of, 157 intensity-modulated, versus 3DCRT and Mammosite, for partial breast irradiation, dosimetric comparison of, 183 Radiation Therapy Oncology Group (RTOG) permanent prostate implant protocol for localized adenocarcinoma, quality assurance in, 152 Real-time dosimetry CT-based postplanning, during ultrasound-guided brachytherapy for prostate cancer, 147 Rectum comparison of ICBT doses based on orthogonal films and CECT in cervical cancer, 223 Recurrence. see Cancer recurrence Right coronary artery (RCA) prostate brachytherapy seed migration to, in association with AMI (case report), 262 Robotics in transrectal ultrasound-guided prostate brachytherapy, phantom experiment, 14 RTOG 0019 descriptive analysis of postimplant dosimetry from, 239
S Salvage surgery and PHDRB, in previously irradiated head and neck cancer patients, 32 Seed implantation for prostate brachytherapy, technique to determine accurate urethral
Subject Index / Brachytherapy 5 (2006) 268–271 dosimetry after, 27 suture-embedded versus loose, for prostate brachytherapy, postimplant dosimetry and embolization rates of, 165 unstranded versus customized stranded, in TIPPB, dosimetry of, 244 Seed migration prostate brachytherapy, to RCA in association with AMI (case report), 262 to the vertebral venous plexus after 125I transperineal interstitial permanent prostate brachytherapy (case report), 127 Single source breast brachytherapy (SSB) versus EFTB, for left breast cancer, lung and cardiac tissue doses in, 235
T Technology advances in radiation oncology, medical malpractice and (case report), 131 commentary (editorial), 135 Three-dimensional conformal radiation therapy (3DCRT) versus IMRT and Mammosite, for partial breast irradiation, dosimetric comparison of, 183 Transperineal interstitial permanent prostate seed brachytherapy (TIPPB) dosimetric analysis of USS versus CSS in, 244 Transrectal ultrasound -based postimplant dosimetry, effect of interobserver variability on, 174 robot-assisted, in prostate brachytherapy, phantom experiment, 14 Treatment planning for interstitial and intracavitary high-dose-rate brachytherapy, quality assurance of, 56 intraoperative versus preplanning, of low-dose-rate brachytherapy for prostate cancer, 139 counterpoint, 143 rebuttal, 146
271
rebuttal, 145 real-time CT-based postplanning dosimetry during ultrasound-guided brachytherapy for prostate cancer, 147 Tumor comparison of ICBT doses based on orthogonal films and CECT in cervical cancer, 223
U Ultrasound -guided brachytherapy, for prostate cancer, real-time CT-based postplanning dosimetry during, 147 robot-assisted transrectal, in prostate brachytherapy, phantom experiments, 14 transrectal, postimplant dosimetry based on, effect of interobserver variability on, 174 Unstranded seed (USS) versus CSS, in TIPPB, dosimetry of, 244 Urethral dose in seed brachytherapy for prostate cancer, technique to determine accuracy of, 27 Urinary morbidity relation to catheterization and International Prostate Symptom score after 125I prostate brachytherapy, 9 Uterine cancer medically inoperable, twice-daily high-dose-rate brachytherapy for, 118
V Vaginal cancer and cervical cancer, outcomes of high-dose-rate brachytherapy with EBRT for, 218 Venous plexus vertebral, seed migration to, after 125I transperineal interstitial permanent prostate brachytherapy (case report), 127
Subject Index to Volume 5
A Abstracts American Brachytherapy Society annual meeting presentations, 70 Acute myocardial infarction (AMI) prostate brachytherapy seed migration to RCA in association with (case report), 262 Adenocarcinoma localized, quality assurance in RTOG permanent prostate implant protocol for, 152 prostate, dosimetry of permanent implant versus high-dose-rate brachytherapy for, 251 American Brachytherapy Society annual meeting presentations, 70
B Bladder comparison of ICBT doses based on orthogonal films and CECT in cervical cancer, 223 Book review Crook: Basic and Advanced Techniques in Prostate Brachytherapy, Vol. 4, p. 304; erratum, 61 Brachytherapy dosimetric comparison of 3DCRT and IMRT and Mammosite for partial breast irradiation, 183 high-dose-rate endobronchial, versus with EBRT, for symptom palliation in patients with non–small-cell lung cancer, 189 intracavitary and interstitial, high-dose-rate, quality assurance of treatment plans for, 56 low-dose-rate versus high-dose-rate, for cervical cancer, outcomes of, 49 seed, for prostate cancer, technique to determine accurate urethral dosimetry after, 27 single-dose, for dysphagia palliation in esophageal cancer, predictors of outcomes of, 41 ultrasound-guided, for prostate cancer, real-time CT-based postplanning dosimetry during, 147 Breast brachytherapy single source, versus EBTF, for left breast cancer, lung and cardiac tissue doses in patients, 235 Breast cancer. see also Breast brachytherapy dosimetric comparison of 3DCRT and IMRT and Mammosite, 183 early-stage, evaluation of surface radiation dose and dose gradient using Mammosite applicator, 230 left, lung and cardiac tissue doses in SSB versus EBTF for, 235
C Cancer recurrence gynecologic, PHDRB for, 203
1538-4721/06/$ – see front matter doi:10.1016/S1538-4721(06)00273-X
Catheterization relation to urinary morbidity and International Prostate Symptom score after 125I prostate brachytherapy, 9 Cervical cancer comparison of ICBT doses to tumor, rectum and bladder based on orthogonal films and CECT in, 223 outcomes of low-dose-rate ICBT versus high-dose-rate ICBT for, 49 and vaginal cancer, outcomes of high-dose-rate brachytherapy with EBRT for, 218 Computed tomography (CT) contrast enhanced, versus orthogonal films, comparison of ICBT doses to tumor, bladder and rectum, 223 real-time, for postplanning dosimetry during ultrasound-guided brachytherapy for prostate cancer, 147 Contrast enhanced computed tomography (CECT) versus orthogonal films, in comparison of ICBT doses to tumor, bladder and rectum, 223 Coronary artery right, prostate brachytherapy seed migration to, in association with AMI (case report), 262 Customized stranded seed (CSS) versus USS, in TIPPB, dosimetry of, 244
D Dose escalation of high-dose-rate brachytherapy boost for prostate cancer, outcomes of, 256 Dose homogeneity in early stage breast cancer using Mammosite applicator, evaluation of, 230 Dosimetry in 3DCRT versus IMRT and Mammosite for partial breast irradiation, 183 in high-dose-rate brachytherapy versus permanent implant for prostate adenocarcinoma, 251 in ICBT, to tumor, rectum and bladder based on orthogonal films and CECT, 223 postimplant descriptive analysis from RTOG 0019, 239 and embolization rates, of suture-embedded versus loose seed implants for prostate brachytherapy, 165 transrectal ultrasonography, effect of interobserver variability on, 174 real-time CT-based postplanning, during ultrasound-guided brachytherapy for prostate cancer, 147 urethral, after seed brachytherapy for prostate cancer, technique to determine accuracy of, 27 of USS versus CSS, in TIPPB, 244 Dysphagia palliation in esophageal cancer, predictors of outcomes of single-dose brachytherapy for, 41
Subject Index / Brachytherapy 5 (2006) 268–271 E
I
Embolization rates and postimplant dosimetry, of suture-embedded versus loose seed implants for prostate brachytherapy, 165 Esophageal cancer predictors of outcomes of single-dose brachytherapy for dysphagia palliation in, 41 External beam radiation therapy (EBRT) versus with HDREB, for symptom palliation in patients with non–small-cell lung cancer, 189 with high-dose-rate brachytherapy, for gynecologic cancer, outcomes of, 218 with three-dimensional computer-optimized high-dose-rate brachytherapy, for localized prostate cancer, outcomes of, 157 External beam tangent field (EBTF) versus SSB, for left breast cancer, lung and cardiac tissue doses in, 235
125I
F First fraction optimization (FFO) versus IFO, for multichannel vaginal cuff high-dose-rate brachytherapy, 211; (editorial), 216
G Geometric optimization IFO versus FFO, for multichannel vaginal cuff high-dose-rate brachytherapy, 211; (editorial), 216 Gynecologic cancer cervical and vaginal cancer, outcomes of high-dose-rate brachytherapy with EBRT for, 218 locally advanced and recurrent, PHDRB for, 203
269
prostate brachytherapy relation of International Prostate Symptom score to urinary morbidity and catheterization after, 9 transperineal interstitial permanent, seed migration to the vertebral venous plexus (case report), 127 Image guidance phantom experiments of robot-assisted transrectal ultrasound in prostate brachytherapy, 14 Individual fraction optimization (IFO) versus FFO, for multichannel vaginal cuff high-dose-rate brachytherapy, 211; (editorial), 216 Intensity-modulated radiation therapy (IMRT) versus 3DCRT and Mammosite, for partial breast irradiation, dosimetric comparison of, 183 International Prostate Symptom score relation to urinary morbidity and catheterization after 125I prostate brachytherapy, 9 Interobserver variability effect on transrectal ultrasonography-based postimplant dosimetry, 174 Interstitial brachytherapy and ICBT, high-dose-rate, quality assurance of treatment plans for, 56 transperineal permanent prostate dosimetric analysis of USS versus CSS in, 244 125I, seed migration to the vertebral venous plexus (case report), 127 Intracavitary brachytherapy (ICBT) doses to tumor, rectum and bladder based on orthogonal films and CECT, 223 high-dose-rate versus low-dose-rate, for cervical cancer, outcomes of, 49 and interstitial brachytherapy, high-dose-rate, quality assurance of treatment plans for, 56
L H Head and neck cancer PHDRB and salvage surgery in previously irradiated patients with, 32 Heart tissue doses, in SSB versus EBTF for left breast cancer, 235 High-dose-rate brachytherapy boost, outcomes of dose escalation trial for prostate cancer, 256 with EBRT, for gynecologic cancer, outcomes of, 218 intracavitary and interstitial, quality assurance of treatment plans for, 56 versus low-dose-rate ICBT, for cervical cancer, outcomes of, 49 versus low-dose-rate brachytherapy, in prostate cancer treatment, 1 counterpoint, 5 rebuttal, 8 rebuttal, 7 Mammosite, evaluation of surface radiation dose and dose gradient in early stage breast cancer using, 230 multichannel vaginal cuff, IFO versus FFO for, 211; (editorial), 216 perioperative for locally advanced and recurrent gynecologic cancer, 203 and salvage surgery, in previously irradiated head and neck cancer patients, 32 versus permanent implant, for prostate adenocarcinoma, dosimetry of, 251 three-dimensional computer-optimized, with EBRT, for localized prostate cancer, outcomes of, 157 twice-daily, for medically inoperable uterine cancer, 118 High-dose-rate endobronchial brachytherapy (HDREB) versus with EBRT, for symptom palliation in patients with non–small-cell lung cancer, 189 Hypofractionation in high-dose-rate brachytherapy boost for prostate cancer, outcomes of, 256
Low-dose-rate brachytherapy versus high-dose-rate brachytherapy, in prostate cancer treatment, 1 counterpoint, 5 rebuttal, 8 rebuttal, 7 intracavitary, versus high-dose-rate brachytherapy, for cervical cancer, outcomes of, 49 for prostate cancer, preplanning versus intraoperative planning, 139 counterpoint, 143 rebuttal, 146 rebuttal, 145 Lung cancer non–small-cell, HDREB versus with EBRT for symptom palliation in patients with, 189 Lung tissue doses, in SSB versus EBTF for left breast cancer, 235
M Mammosite versus 3DCRT and IMRT, for partial breast irradiation, dosimetric comparison of, 183 evaluation of surface radiation dose and dose gradient in early stage breast cancer using, 230 Medical malpractice in radiation oncology (case report), 131 commentary (editorial), 135 Multichannel vaginal cuff high-dose-rate brachytherapy, IFO versus FFO for, 211; (editorial), 216 Myocardial infarction acute, prostate brachytherapy seed migration to RCA in association with (case report), 262
270
Subject Index / Brachytherapy 5 (2006) 268–271
N Non–small-cell lung cancer HDREB versus with EBRT for symptom palliation in patients with, 189
O Orthogonal radiographs versus CECT, in comparison of ICBT doses to tumor, bladder and rectum, 223 Outcomes dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer, 256 high-dose-rate brachytherapy with EBRT for gynecologic cancer, 218 low-dose-rate ICBT versus high-dose-rate ICBT for cervical cancer, 49 single-dose brachytherapy for dysphagia palliation in esophageal cancer, predictors of, 41 three-dimensional computer-optimized high-dose-rate brachytherapy with EBRT for localized prostate cancer, 157
rebuttal, 8 rebuttal, 7 localized, outcomes of three-dimensional computer-optimized highdose-rate brachytherapy with EBRT for, 157 outcomes of dose escalation trial of high-dose-rate brachytherapy boost for, 256 preplanning versus intraoperative planning of low-dose-rate brachytherapy for, 139 counterpoint, 143 rebuttal, 146 rebuttal, 145 real-time CT-based postplanning dosimetry during ultrasound-guided brachytherapy for, 147 technique to determine accurate urethral dosimetry in seed brachytherapy for, 27 Prostate-specific antigen (PSA) bounce of, mimics biochemical relapse after permanent prostate brachytherapy, 122
Q P Palliative treatment single-dose brachytherapy, for dysphagia in esophageal cancer, predictors of outcomes of, 41 of symptoms in patients with non–small-cell lung cancer, HDREB versus with ERB for, 189 Partial breast irradiation dosimetric comparison of 3DCRT and IMRT and Mammosite for, 183 Perioperative high-dose-rate brachytherapy (PHDRB) for locally advanced and recurrent gynecologic cancer, 203 and salvage surgery, in previously irradiated head and neck cancer patients, 32 Permanent implant versus high-dose-rate brachytherapy, for prostate adenocarcinoma, dosimetry of, 251 prostate dosimetric analysis of USS versus CSS in, 244 125I, seed migration to the vertebral venous plexus (case report), 127 for localized adenocarcinoma, quality assurance in RTOG protocol of, 152 Phantom experiments of robot-assisted transrectal ultrasound in prostate brachytherapy, 14 Prostate adenocarcinoma dosimetry of permanent implant versus high-dose-rate brachytherapy for, 251 Prostate brachytherapy descriptive analysis of postimplant dosimetry from RTOG 0019, 239 effect of interobserver variability on transrectal ultrasonography-based postimplant dosimetry, 174 125I relation of International Prostate Symptom score to urinary morbidity and catheterization after, 9 transperineal interstitial permanent, seed migration to the vertebral venous plexus (case report), 127 permanent for localized adenocarcinoma, quality assurance in RTOG protocol of, 152 PSA bounce mimics biochemical relapse after, 122 transperineal interstitial, dosimetric analysis of USS versus CSS in, 244 with robot-assisted transrectal ultrasound guidance, phantom experiments, 14 seed migration to RCA in association with AMI (case report), 262 using suture-embedded and loose seed implants, postimplant dosimetry and embolization rates of, 165 Prostate cancer. See also Prostate brachytherapy high-dose-rate versus low-dose-rate brachytherapy for, 1 counterpoint, 5
Quality assurance in RTOG permanent prostate implant protocol for localized adenocarcinoma, 152 of treatment plans for interstitial and intracavitary high-dose-rate brachytherapy, 56
R Radiation dose surface, in early stage breast cancer using Mammosite applicator, evaluation of, 230 Radiation oncology medical malpractice crisis in (case report), 131 commentary (editorial), 135 Radiation therapy external beam with high-dose-rate brachytherapy, for gynecologic cancer, outcomes of, 218 with three-dimensional computer-optimized high-dose-rate brachytherapy, for localized prostate cancer, outcomes of, 157 intensity-modulated, versus 3DCRT and Mammosite, for partial breast irradiation, dosimetric comparison of, 183 Radiation Therapy Oncology Group (RTOG) permanent prostate implant protocol for localized adenocarcinoma, quality assurance in, 152 Real-time dosimetry CT-based postplanning, during ultrasound-guided brachytherapy for prostate cancer, 147 Rectum comparison of ICBT doses based on orthogonal films and CECT in cervical cancer, 223 Recurrence. see Cancer recurrence Right coronary artery (RCA) prostate brachytherapy seed migration to, in association with AMI (case report), 262 Robotics in transrectal ultrasound-guided prostate brachytherapy, phantom experiment, 14 RTOG 0019 descriptive analysis of postimplant dosimetry from, 239
S Salvage surgery and PHDRB, in previously irradiated head and neck cancer patients, 32 Seed implantation for prostate brachytherapy, technique to determine accurate urethral
Subject Index / Brachytherapy 5 (2006) 268–271 dosimetry after, 27 suture-embedded versus loose, for prostate brachytherapy, postimplant dosimetry and embolization rates of, 165 unstranded versus customized stranded, in TIPPB, dosimetry of, 244 Seed migration prostate brachytherapy, to RCA in association with AMI (case report), 262 to the vertebral venous plexus after 125I transperineal interstitial permanent prostate brachytherapy (case report), 127 Single source breast brachytherapy (SSB) versus EFTB, for left breast cancer, lung and cardiac tissue doses in, 235
T Technology advances in radiation oncology, medical malpractice and (case report), 131 commentary (editorial), 135 Three-dimensional conformal radiation therapy (3DCRT) versus IMRT and Mammosite, for partial breast irradiation, dosimetric comparison of, 183 Transperineal interstitial permanent prostate seed brachytherapy (TIPPB) dosimetric analysis of USS versus CSS in, 244 Transrectal ultrasound -based postimplant dosimetry, effect of interobserver variability on, 174 robot-assisted, in prostate brachytherapy, phantom experiment, 14 Treatment planning for interstitial and intracavitary high-dose-rate brachytherapy, quality assurance of, 56 intraoperative versus preplanning, of low-dose-rate brachytherapy for prostate cancer, 139 counterpoint, 143 rebuttal, 146
271
rebuttal, 145 real-time CT-based postplanning dosimetry during ultrasound-guided brachytherapy for prostate cancer, 147 Tumor comparison of ICBT doses based on orthogonal films and CECT in cervical cancer, 223
U Ultrasound -guided brachytherapy, for prostate cancer, real-time CT-based postplanning dosimetry during, 147 robot-assisted transrectal, in prostate brachytherapy, phantom experiments, 14 transrectal, postimplant dosimetry based on, effect of interobserver variability on, 174 Unstranded seed (USS) versus CSS, in TIPPB, dosimetry of, 244 Urethral dose in seed brachytherapy for prostate cancer, technique to determine accuracy of, 27 Urinary morbidity relation to catheterization and International Prostate Symptom score after 125I prostate brachytherapy, 9 Uterine cancer medically inoperable, twice-daily high-dose-rate brachytherapy for, 118
V Vaginal cancer and cervical cancer, outcomes of high-dose-rate brachytherapy with EBRT for, 218 Venous plexus vertebral, seed migration to, after 125I transperineal interstitial permanent prostate brachytherapy (case report), 127